{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T20:06:01Z","timestamp":1793563561550,"version":"4.5.0"},"reference-count":10,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2010,7,28]],"date-time":"2010-07-28T00:00:00Z","timestamp":1280275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2010,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Coenzyme Q10 (CoQ<jats:sub>10<\/jats:sub>), a potential neuroprotective compound, was previously investigated at a dosage of 600 mg\/day in Huntington's disease (HD) patients and demonstrated a trend toward slowing disease progression. Higher CoQ<jats:sub>10<\/jats:sub> dosages may prove beneficial. We investigated the tolerability and blood levels associated with 1,200, 2,400, and 3,600 mg\/day of CoQ<jats:sub>10<\/jats:sub> in HD and healthy subjects. Twenty\u2010eight subjects (20 HD, 8 healthy) enrolled in a 20\u2010week open\u2010label trial. Subjects started on 1,200 mg\/day of CoQ<jats:sub>10<\/jats:sub>, increasing every 4 weeks by 1,200 mg to a maximum dosage of 3,600 mg\/day. Monthly evaluations included review of adverse events and CoQ<jats:sub>10<\/jats:sub> blood levels. Twenty\u2010three subjects (82%) achieved the target dosage of 3,600 mg\/day. Six subjects (2 healthy, 4 HD) withdrew prematurely (gastrointestinal (GI) symptoms in 3, worsening HD in 2, and 1 because of a fall). All three serious adverse events occurred in a single subject, and were deemed unrelated to CoQ<jats:sub>10<\/jats:sub>. The most common adverse events seen were GI symptoms. Mean (\u00b1 SD) CoQ10 blood levels achieved over the course of the trial were as follows: 1.26 \u00b1 1.27 \u03bcg\/mL (baseline, n = 28), 5.59 \u00b1 2.24 \u03bcg\/mL (1,200 mg\/day, week 4, n = 26), 6.38 \u00b1 3.25 \u03bcg\/mL (2,400 mg\/day, week 8, n = 25), 7.49 \u00b1 4.09 \u03bcg\/mL (3,600 mg\/day, week 12, n = 23), and 6.78 \u00b1 3.36\u03bcg\/mL (3,600 mg\/day, week 20, n = 20). CoQ<jats:sub>10<\/jats:sub> was well tolerated with over 80% of subjects achieving the target dosage. Dosages of 2,400 mg\/day may provide the best balance between tolerability and blood level achieved. Further studies examining the efficacy of 2,400 mg\/day are planned. \u00a9 2010 Movement Disorder Society.<\/jats:p>","DOI":"10.1002\/mds.22408","type":"journal-article","created":{"date-parts":[[2010,7,28]],"date-time":"2010-07-28T21:17:08Z","timestamp":1280351828000},"page":"1924-1928","source":"Crossref","is-referenced-by-count":81,"title":["Safety and tolerability of high\u2010dosage coenzyme Q<sub>10<\/sub> in Huntington's disease and healthy subjects"],"prefix":"10.1002","volume":"25","author":[{"name":"The Huntington Study Group Pre2CARE Investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,9,8]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90585-E"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410410514"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410410206"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(200007)48:1<72::AID-ANA11>3.0.CO;2-I"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.3.397"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.7.849"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410420221"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.29.1.1"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870110204"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2004.05.003"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.22408","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.22408","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.22408","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:34:35Z","timestamp":1760960075000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.22408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,8]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,9,15]]}},"alternative-id":["10.1002\/mds.22408"],"URL":"https:\/\/doi.org\/10.1002\/mds.22408","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,8]]}}}